EA201300034A1 - PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM - Google Patents

PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM

Info

Publication number
EA201300034A1
EA201300034A1 EA201300034A EA201300034A EA201300034A1 EA 201300034 A1 EA201300034 A1 EA 201300034A1 EA 201300034 A EA201300034 A EA 201300034A EA 201300034 A EA201300034 A EA 201300034A EA 201300034 A1 EA201300034 A1 EA 201300034A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical compositions
compositions containing
ways
Prior art date
Application number
EA201300034A
Other languages
Russian (ru)
Other versions
EA029416B1 (en
Inventor
Сайсива Прасад Равула
Ананд Кумар Мамиди
Original Assignee
Заклады Фармацеутицне Польфарма Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Заклады Фармацеутицне Польфарма Са filed Critical Заклады Фармацеутицне Польфарма Са
Publication of EA201300034A1 publication Critical patent/EA201300034A1/en
Publication of EA029416B1 publication Critical patent/EA029416B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Abstract

Предметом изобретения являются фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения.The subject of the invention is pharmaceutical compositions containing imatinib or a pharmaceutically acceptable salt thereof, and methods for their preparation.

EA201300034A 2010-06-21 2011-06-17 Tablet comprising imatinib or a pharmaceutically acceptable salt thereof and process for the preparation thereof EA029416B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1732CH2010 2010-06-21
EP10460039 2010-09-20
PCT/EP2011/003020 WO2011160798A1 (en) 2010-06-21 2011-06-17 Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof

Publications (2)

Publication Number Publication Date
EA201300034A1 true EA201300034A1 (en) 2013-05-30
EA029416B1 EA029416B1 (en) 2018-03-30

Family

ID=44358103

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300034A EA029416B1 (en) 2010-06-21 2011-06-17 Tablet comprising imatinib or a pharmaceutically acceptable salt thereof and process for the preparation thereof

Country Status (4)

Country Link
EP (1) EP2582362A1 (en)
EA (1) EA029416B1 (en)
PL (1) PL234542B1 (en)
WO (1) WO2011160798A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750700B2 (en) * 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
JP5928159B2 (en) * 2012-05-28 2016-06-01 ニプロ株式会社 Pharmaceutical composition
EP2749271A1 (en) * 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Optimized manufacturing method and pharmaceutical formulation of imatinib
GB201304699D0 (en) * 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
CN104414988B (en) * 2013-08-28 2018-07-06 山东新时代药业有限公司 A kind of Dasatinib tablet and its preparation process
WO2017129624A1 (en) * 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
CN114259497A (en) * 2016-07-26 2022-04-01 江苏豪森药业集团有限公司 Pharmaceutical composition of aminopyrimidine compounds and preparation method thereof
WO2019016673A2 (en) * 2017-07-20 2019-01-24 Kashiv Pharma Llc A stable oral pharmaceutical composition of imatinib
KR20220035421A (en) * 2019-07-15 2022-03-22 노파르티스 아게 Formulation of (S)-3-amino-6-methoxy-N-picolinamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1762230B2 (en) * 2005-08-15 2016-04-20 Siegfried International AG Filmtablet or granulate comprising a pyridylpyrimidine
WO2009042803A1 (en) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Imatinib compositions

Also Published As

Publication number Publication date
WO2011160798A1 (en) 2011-12-29
PL234542B1 (en) 2020-03-31
EA029416B1 (en) 2018-03-30
PL402710A1 (en) 2013-09-30
EP2582362A1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
EA201300034A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM
EA201590930A1 (en) DOSAGE FORMS OF RUXOLITINIB WITH Slow Release.
EA201270741A1 (en) ORAL COMPOSITIONS AND LIPOPHYL SALTS OF METHylNALTREX
EA201791717A1 (en) STABLE WATER COMPOSITIONS ADALIMUMAB
IN2014MN02598A (en)
EA201590931A1 (en) HETEROCYCLIC SUBSTITUTED DERIVATIVES 2-AMINO-HINAZOLINE FOR THE TREATMENT OF VIRAL INFECTIONS
EA201790781A2 (en) ANTI-VIRUS COMPOUNDS
EA201890333A1 (en) ANTI-VIRUS COMPOUNDS
EA201171151A1 (en) CRYSTALLINE TRIPEPTIDE EPOXYKETON-PROTEASE INHIBITORS
EA201290772A1 (en) NEW FORMS OF IVABRADIN HYDROCHLORIDE
EA201401351A1 (en) DERIVATIVES OF BENZIMIDAZOL-PROLINE
EA201390908A1 (en) DERIVATIVES OF BICYCLO [3.2.1] OCTYLAMIDE AND THEIR APPLICATION
EA201591728A1 (en) HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR APPLICATION
EA201691216A1 (en) COMPOUNDS OF LINACLOTIDE WITH Slow Release
EA201500383A1 (en) DERIVATIVES 1,2,4-TRIAZINE FOR THE TREATMENT OF VIRAL INFECTIONS
EA201490037A1 (en) ANTAGONISTS TRPV4
EA201300388A1 (en) COMPOUNDS OF SUBSTITUTED BENZAMIDE
EA201590520A1 (en) PHARMACEUTICAL COMPOSITION WITH COATING CONTAINING REGORAPHENIB
EA201492287A1 (en) DEUTERED DERIVATIVES RUXOLITINIBA
EA201490471A1 (en) PYRIDAZINOUS COMPOUNDS AND THEIR APPLICATION AS DAAO INHIBITORS
EA201500628A1 (en) INDOLKARBOXAMID DERIVATIVES AS ANTAGONISTS OF P2XRECEPTORS
EA201291211A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE
EA201400623A1 (en) NEW 2H-INDASOLS AS ANTAGONISTS EP EPCEPTOR
EA201490222A1 (en) COMBINED COMPOSITIONS BASED ON DARUNAVIR
EA201490223A1 (en) COMPOSITIONS BASED ON DARUNAVIR

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU